Benefits
DashboardNot registered yet? Get a free account.
Sign Up
METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED
Leave site?
You're about to leave our website and go to an external link. Are you sure?
Active
Updated: 13 Dec 2023
Metro Lifesciences Hospital Private Limited, is an unlisted private company incorporated on 27 April, 2009. It is classified as a private limited company and is located in Patna, Bihar. It's authorized share capital is INR 5.00 lac and the total paid-up capital is INR 5.00 lac.
The current status of Metro Lifesciences Hospital Private Limited is - Active.
Read more
Buy Dashboard using Credits
Just a Quick Check!
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
Industry
Other service activites
Key Metrics
** All rupee values in INR crores. Based on March 2024 numbers.
Total Revenue
8.9%
8.9%
EBITDA
7.69%
7.69%
Net Profit
-68.97%
-68.97%
Networth
2.15%
2.15%
Borrowings
6.23%
6.23%
Assets
5.07%
5.07%
Gross Margin
5.57
5.57
Operating Margin
-0.31
-0.31
Net Profit Margin
-8.37
-8.37
Return on Equity
-8.01
-8.01
ROCE
-0.76
-0.76
Debt to Equity
0.01
0.01
Sales
Mar 2024
Net worth
Mar 2024
Buy Report or Plans
Dashboards
Popular Plan-
₹ 449
Company dashboard-
Five year financials and ratios
-
Risk analysis
-
Interactive charts
-
View subscriptions
and
buy credits 
MCA Fillings
-
₹ 349
All financials
-
All financials
-
All annual returns
-
MoA and AoA
-
-
₹ 249
1 Year
-
Latest financials
-
Latest annual return
-
MoA and AoA
-
PDF Reports
-
₹ 799
Financial report
-
Five year financials and ratios
-
Shareholding and group structure
-
Litigation and more
-
-
₹ 2999
Due diligence report
-
Everything in financial report
-
Peers and financials
-
* GST not included
** Reports & MCA filings will be based on the latest available financials.
Locations
India
(1)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Select Tags
Choose Location
Tofler Score
Poor
Fair
Good
Very Good
Excellent
Risk
Severe Risk
- No risks identified
Moderate Risk
- No risks identified
Low Risk
- No risks identified
About Tofler Score
Tofler Score measures the quality of performance and integrity of a company. It is
dependent on three key factors - Sustainability, Governance, and Growth.
Read more
Financial Highlights
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Margins
Gross margin
Operating margin
Net margin
Balance Sheet
₹
%
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total assets
Profit & Loss
₹
%
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Revenue from operations
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Ratios
Current ratio
Debt/equity ratio
Charges on assets
As per information available, the company has no registered charges.
People
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Satish Kumar | 02178872 | 16 years |
| Director | Indrajit Singh | 02506519 | 16 years |
| Director | Kamlesh Kumar Singh | 02506531 | 16 years |
Company Network
Expand
Delete
Collapse
See
details
Companies connected through Directors
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| MEDICAN PHARMA PRIVATE LIMITED |
Active
|
10.0 L | 1 | Bihar |
| RAGHOTHAM HOTEL PRIVATE LIMITED |
Active
|
5.0 L | 1 | Jharkhand |
Registered Details
CIN
U93000BR2009PTC014461PAN
-Incorporation
2009, 16.0 yearsCompany Email
metrohospitalpvtltd@gmail.comPaid up Capital
₹ 5.0 LAuthorised Capital
₹ 5.0 LAGM
Sep 2023Type
Private
Non-government Company
FAQ - METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED
What is the incorporation date of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED?
The incorporation date of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED is 27 April, 2009
What is the authorized share capital of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED?
The authorized share capital of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED is INR ₹ 5.0 L.
What is the paid-up capital of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED?
The paid-up capital of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED is INR ₹ 5.0 L.
What is the registered address of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED?
The registered address of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED is HANUMAN NAGAR NEAR KHEMNI CHAK MORE PATNA Bihar - 800020
What is the CIN number of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED?
The CIN number of METRO LIFESCIENCES HOSPITAL PRIVATE LIMITED is U93000BR2009PTC014461.
Tofler, TWS Systems Private Limited and its officers respect the Intellectual Property Rights of all
people. Tofler makes no claim of ownership or affiliation with any trademark (REGISTERED OR
UNREGISTERED) that forms part of any Company/LLP name listed on this page. Trademarks, if any,
listed on
this page belong to...
Read
More
